生物降解的聚合物微球配方的全长抗VEGF抗体贝瓦西祖马布持续眼内输送
Shwetha Iyer1,2, Cameron Lee2, Mansoor M Amiji3,4
1Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, Northeastern University, Boston, MA, 02115, USA.
Drug delivery and translational research
|January 24, 2025
概括
研究人员为抗VEGF抗体贝瓦齐祖马布开发了缓释微球,用于治疗与年龄相关的黄斑变性 (AMD). 这种新的注射方法可以减少治疗频率,并改善患者的遵守性.
科学领域:
- 眼科和生物医学工程眼科和生物医学工程
背景情况:
- 与年龄相关的黄斑变性 (AMD) 是老年人视力丧失的主要原因.
- 目前的治疗方法,比如贝瓦西祖马布,需要频繁的视内注射,影响患者的坚持.
- 一个新的端口输送系统提供更长的间隔,但需要手术植入.
研究的目的:
- 使用聚合物微球开发一种患者友好的,可注射的缓释配方,用于bevacizumab.
- 评估聚乙烯-烯酸 (PCL) 适用于封装像贝瓦西祖马布这样的大型蛋白质治疗药物的适用性.
主要方法:
- 研究了用于微球制造的多D,L-乳酸-协同甘化物 (PLGA) 和多-烯酸 (PCL) 聚合物.
- 使用双重乳液方法在PCL微球中封装贝瓦西祖马布.
- 评估了封装贝瓦西祖马布的体外释放特征.
主要成果:
- 聚乙烯-烯酸 (PCL) 已被证明是有效的封装大抗体治疗.
- 微球成功封装了bevacizumab,证明了活性剂的持续释放.
- 生物活性贝瓦西祖马布从PCL微球中释放长达60天.
结论:
- 可注射的聚合物微球为持续输送抗VEGF抗体提供了一个有希望的替代方案.
- 这种方法可以显著提高AMD的治疗方便性和患者的治疗结果.
- 对这种新型药物输送系统的进一步研究有可能促进眼科治疗的发展.
相关概念视频
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...


